|
EGR3 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 2.25979999999293E-05 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
5.92429999999311E-05 |
| Normal-vs-Stage2 |
4.17440000000102E-06 |
| Normal-vs-Stage3 |
3.80469999999855E-05 |
| Normal-vs-Stage4 |
1.89369999999967E-05 |
| Stage1-vs-Stage2 |
1.847030E-01 |
| Stage1-vs-Stage3 |
6.429800E-01 |
| Stage1-vs-Stage4 |
3.741600E-01 |
| Stage2-vs-Stage3 |
4.305800E-01 |
| Stage2-vs-Stage4 |
6.885600E-01 |
| Stage3-vs-Stage4 |
6.983000E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
5.63599999999775E-05 |
| Normal-vs-AfricanAmerican |
2.00229999999246E-05 |
| Normal-vs-Asian |
3.64440000000243E-05 |
| Caucasian-vs-AfricanAmerican |
3.361000E-01 |
| Caucasian-vs-Asian |
6.472200E-01 |
| AfricanAmerican-vs-Asian |
5.757000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
9.20570000007004E-07 |
| Normal-vs-Female |
7.64140000000246E-05 |
| Male-vs-Female |
3.184500E-03 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
8.49370000000071E-05 |
| Normal-vs-Age(41-60Yrs) |
3.51729999999995E-05 |
| Normal-vs-Age(61-80Yrs) |
3.15189999999799E-06 |
| Normal-vs-Age(81-100Yrs) |
2.114600E-01 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
5.356000E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
1.343240E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
4.389000E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
4.156400E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
3.526000E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
3.312800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
5.006100E-02 |
| Classical-VS-Follicular |
5.861400E-01 |
| Classical-VS-Other |
6.247400E-01 |
| Classical-VS-Normal |
2.3818999999925E-05 |
| Tall-VS-Follicular |
1.525360E-01 |
| Tall-VS-Other |
7.578200E-01 |
| Tall-VS-Normal |
1.3979999999858E-06 |
| Follicular-VS-Other |
4.183800E-01 |
| Follicular-VS-Normal |
1.480660E-03 |
| Other-VS-Normal |
5.437800E-04 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.676549999996E-05 |
| Normal-vs-N1 |
1.94568999999367E-05 |
| N0-vs-N1 |
8.954600E-01 |
|
|
